Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8188491 | 0.84 | NPC1 (0.50) | NPC1HPGDRAB9A | |
| SCHEMBL7142157 | 0.80 | CHRNB2 (0.38) | NPC1HPGDRAB9AADRA2AFFAR1 | |
| SCHEMBL4101527 | 0.79 | SPHK2 (0.47) | FFAR1CHRNB4CHRNA3CHRNB2CHRNA5 | |
| SCHEMBL7246915 | 0.79 | NPC1 (0.45) | NPC1HPGDRAB9AFFAR1CHRNB4 | |
| SCHEMBL4101521 | 0.79 | SPHK2 (0.47) | FFAR1CHRNB4CHRNA3CHRNB2CHRNA5 | |
| SCHEMBL22462974 | 0.76 | KMT2A (0.42) | HPGDCHRNB4CHRNA3 | |
| SCHEMBL4504683 | 0.75 | CHRNB4 (0.35) | NPC1HPGDRAB9ACHRNB4CHRNA3 | |
| SCHEMBL8639404 | 0.73 | LTA4H (0.46) | NPC1HPGDRAB9A | |
| SCHEMBL8120916 | 0.71 | FFAR1 (0.44) | FFAR1 | |
| SCHEMBL8637065 | 0.71 | LTA4H (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576134-B1 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2013-03-06 | — | — | EP | claimed |
| US-20130045487-A1 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | NEURALSTEM, INC. (US) | 2013-02-21 | — | — | US | claimed |
| US-8293488-B2 | Drug screening; exposing to cultures of differentiating neural progenitor cells; Alzheimer's disease | NEURALSTEM, INC. (US) | 2012-10-23 | — | — | US | claimed |
| WO-2004053071-A9 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2012-08-16 | — | — | WO | claimed |
| US-20080057530-A1 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | NEURALSTEM, INC. (US) | 2008-03-06 | — | — | US | claimed |
| EP-1576134-A4 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2007-05-30 | — | — | EP | claimed |
| EP-1576134-A2 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | Kelleher-Andersson, Judith (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040185429-A1 | for drug screening and prevention of neurodegenerative and neuropsychiatric disorders; neuroprotectants; for increasing cell volume | KELLEHER-ANDERSSON JUDITH (US) | 2004-09-23 | — | — | US | claimed |
| WO-2004053071-A2 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2004-06-24 | — | — | WO | claimed |
| US-8846914-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140147424-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8674098-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130195816-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-1576134-B1 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2013-03-06 | — | — | EP | disclosed |
| US-7858628-B2 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100034784-A1 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7560553-B1 | 1-(Pyrid-4-yl-methyl-),4-((6-piperazino)pyrid-5-yl)-piperazine; proliferation/differentiation of human hippocampal multipotent stem/progenitor cells and neuronal progenitors; drug screening; learning enhancement; cognition activators; Alzheimer's disease; antidepressants; brain trauma; neuroprotectants | NEURALSTEM, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1576134-A4 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1576134-A2 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | Kelleher-Andersson, Judith (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004053071-A2 | METHOD FOR DISCOVERING NEUROGENIC AGENTS | KELLEHER-ANDERSSON JUDITH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034784-A1 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | DCX, MKI67, INA | NPC1 2645/4885HPGD 1249/4885RAB9A 2936/4885 |
| US-20140147424-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | NPC1 2894/4885HPGD 984/4885RAB9A 2817/4885 |
| US-20130195816-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | NPC1 2894/4885HPGD 984/4885RAB9A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.